Company News
Biocon Secures Early Pebrilzo Launch in Patent Settlement
Biocon entered a global patent settlement and license agreement with Genentech for its biosimilar Pebrilzo® (bPertuzumab).
The agreement enables earliest licensed launches: EU/UK in Q1 CY2027, US in Q
